The role of tau phosphorylation and cleavage in neuronal cell death.

@article{Chun2007TheRO,
  title={The role of tau phosphorylation and cleavage in neuronal cell death.},
  author={Wanjoo Chun and Gail V. W. Johnson},
  journal={Frontiers in bioscience : a journal and virtual library},
  year={2007},
  volume={12},
  pages={
          733-56
        }
}
  • W. Chun, G. Johnson
  • Published 2007
  • Biology, Medicine
  • Frontiers in bioscience : a journal and virtual library
The microtubule-associated protein tau is the primary component of the intracellular filamentous deposits found in Alzheimer's disease (AD) brain and also in a family of neurodegenerative diseases called 'tauopathies', where tau pathology is the primary, defining characteristic with little or no amyloid-beta (Abeta) pathology. It has been demonstrated that tau modifications such as hyperphosphorylation and truncation might be important events in the process leading to tau intracellular… Expand
The Importance of Tau Phosphorylation for Neurodegenerative Diseases
TLDR
The evidence showing that tau phosphorylation plays a key role in neurodegenerative tauopathies is reviewed and the tractability of alteringosphorylation-dependent tau functions for therapeutic intervention in AD and related disorders is commented on. Expand
Structure and Pathology of Tau Protein in Alzheimer Disease
TLDR
The normal structure and function of tau protein and its major alterations during its pathological aggregation in AD are described. Expand
Tau Protein: Function and Pathology
TLDR
Findings supported the concept that amyloid toxicity is tau dependent and that blocking/reducing the pathological effects of tau may be protective against the harmful effects of amyloids pathology, a concept that has indeed proven feasibility in various studies. Expand
Tau as a therapeutic target for Alzheimer's disease.
TLDR
Wide ranging therapeutic approaches that are being developed include to inhibit tau kinases, to enhance phosphatase activity, to promote microtubule stability, and to reduce tau aggregate formation and/or enhance their clearance with small molecule drugs or by immunotherapeutic means. Expand
Tau and tauopathies.
TLDR
This chapter provides an overview of tau structure, functions, and its involvement in neurodegenerative diseases. Expand
Cdk5 regulates the phosphorylation of tyrosine 1472 NR2B and the surface expression of NMDA receptors
Tau aggregation is one of the major features in Alzheimer's disease and in several other tauopathies, including frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), andExpand
The role of β-amyloid peptide in neurodegenerative diseases
TLDR
It is hypothesized that extracellular deposition of β-amyloid peptide fibrils and neurofibrillary tangles represents the body's adaptation mechanism, aimed at preservation of autonomic functioning; while the cognitive decline is severe, the rest of the organ systems remain unaffected and continue to function. Expand
Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer's disease.
TLDR
The results indicate that the early stages of abnormal tau processing are characterized by a sequential appearance of specific phospho-dependent epitope in the form of a cascade of appearance of the antibodies. Expand
Changes in the expression of genes associated with intraneuronal amyloid-beta and tau in Alzheimer's disease.
TLDR
The results suggest that neither intraneuronal Abeta nor phospho-tau has obligatory effects on reducing the expression of genes important for memory and cognition in hippocampus of AD. Expand
Activation of neuronal defense mechanisms in response to pathogenic factors triggering induction of amyloidosis in Alzheimer's disease.
TLDR
A new model for etiology of Alzheimer's disease (AD) is presented which postulates early involvement of specialized neuroprotective mechanisms in the pathology of AD and the evidence related to the possibility that protein hyperphosphorylation may be a byproduct of energetic imbalances in AD cells associated with high levels of protein synthesis is reviewed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 328 REFERENCES
Tau phosphorylation in neuronal cell function and dysfunction
TLDR
Identification of the protein kinases that phosphorylate tau in vivo in both physiological and pathological processes could provide potential therapeutic targets for the treatment of AD and other neurodegenerative diseases in which there is tau pathology. Expand
Tau protein as a differential biomarker of tauopathies.
TLDR
Molecular analysis has revealed that hyperphosphorylation and abnormal phosphorylation might be one of the important events in the process leading to tau intracellular aggregation, suggesting that pathological tau proteins are reliable marker of the neurodegenerative process. Expand
Abnormal tau-containing filaments in neurodegenerative diseases.
TLDR
These diseases show that tau mutations can be a prime cause of inherited dementing illness and may throw some light on the pathological process in the much larger number of sporadic cases of Alzheimer's disease. Expand
Tau pathology in Alzheimer disease and other tauopathies.
TLDR
Inhibition of this tau abnormality is one of the most promising therapeutic approaches to AD and other tauopathies. Expand
Posttranslational modifications of tau--role in human tauopathies and modeling in transgenic animals.
TLDR
Insight is provided into the complexity of tau modifications in human tauopathies such as AD and frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17). Expand
Tau protein and neurodegeneration.
  • M. Goedert
  • Biology, Medicine
  • Seminars in cell & developmental biology
  • 2004
TLDR
The identification of mutations in Tau as the cause of FTDP-17 established that dysfunction or misregulation of tau protein is sufficient to cause neurodegeneration and dementia and is leading to the development of good transgenic animal models of the tauopathies. Expand
Co‐localization of truncated tau and DNA fragmentation in Alzheimer's disease neurones
TLDR
The results suggest that tau truncation is an early intracellular event preceding cell death in AD, and using in situ end labelling of DNA found evidence for DNA fragmentation in a significant subpopulation of MN423-positive neurones. Expand
Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology.
TLDR
It is demonstrated that tau is cleaved at D421 (DeltaTau) by executioner caspases, and therapeutics aimed at inhibiting tau caspase-cleavage may prove beneficial not only in preventing NFT formation, but also in slowing cognitive decline. Expand
Inability of tau to properly regulate neuronal microtubule dynamics: a loss-of-function mechanism by which tau might mediate neuronal cell death.
TLDR
The evidence and arguments for an alternative loss-of-function model in which tau-mediated neuronal cell death is caused by the inability of affected cells to properly regulate their microtubule dynamic due to mis-regulation by tau are described. Expand
Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease
TLDR
Creation of the Tau-C3 epitope appears to occur relatively early in the disease state, contemporaneous with the initial Alz50 folding event that heralds the appearance of filamentous tau in NFTs, neuropil threads, and the dystrophic neurites surrounding amyloid plaques. Expand
...
1
2
3
4
5
...